PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-8.57%
Both companies show declining cash positions (-8.57% vs TRAW's -67.96%). Seth Klarman would examine if this reflects broader market conditions or operational challenges.
No Data
No Data available this quarter, please select a different quarter.
-8.57%
Below half of TRAW's -67.96%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-16.59%
Other current assets growth < half of TRAW's -40.48%. David Dodd sees a leaner approach to short-term items.
-8.67%
Below half of TRAW's -52.21%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
-8.20%
0.5-0.75x TRAW's -14.29%. Martin Whitman might see a risk of falling behind in asset investment or shifting strategy.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
1.26%
Higher Other Non-Current Assets Growth compared to TRAW's zero value, indicating worse performance.
-7.12%
0.5-0.75x TRAW's -13.33%. Martin Whitman wonders if there's insufficient reinvestment vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
-8.62%
Below half of TRAW's -52.18%. Michael Burry sees a potential red flag for stagnation or capital shortage.
-100.00%
Above 1.5x TRAW's -11.37%. Michael Burry questions if payables are being stretched to avoid short-term borrowing.
-100.00%
Higher Short-Term Debt Growth compared to TRAW's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
1405.81%
Less than half of TRAW's -77.40%. David Dodd sees fewer expansions in other current obligations.
-20.28%
1.25-1.5x TRAW's -15.76%. Martin Whitman is wary of bigger short-term burdens.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-0.40%
Less than half of TRAW's -2.09%. David Dodd sees a more conservative approach to non-current liabilities.
No Data
No Data available this quarter, please select a different quarter.
-4.61%
Less than half of TRAW's -12.85%. David Dodd sees far fewer liability expansions relative to competitor.
No Data
No Data available this quarter, please select a different quarter.
-3.23%
≥ 1.5x TRAW's -1.39%. David Dodd sees higher yoy retained profits than competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-12.84%
Below half TRAW's 98.07%. Michael Burry sees potential underperformance in building shareholder capital.
-8.62%
Below half TRAW's -52.18%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
-100.00%
Both TRAW and the company show zero Total Investments Growth.
-7.46%
Higher Total Debt Growth compared to TRAW's zero value, indicating worse performance.
8.60%
Less than half of TRAW's 67.96%. David Dodd sees better deleveraging or stronger cash buildup than competitor.